Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease

Archives of Iranian Medicine

Volumn 10, Issue 2, 2007, Pages 161-167

  Khatibian, Morteza ^a   Ajvadi, Yalda ^a   Nasseri Moghaddam, Siavoush ^a   Ebrahimi Dariani, Naser ^a   Vahedi, Houmayoon ^a   Zendehdel, Nasrin ^a   Sotoudehmanesh, Rasoul ^a   Agah, Shahram ^b   Mikaeli, Javad ^a   Pourshams, Akram ^a   Ali Asgari, Ali ^a   Malekzadeh, Reza ^a   Massarrat, Sadegh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Duodenal ulcer; Eradication; Gastric ulcer; H.pylori

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; FURAZOLIDONE; METRONIDAZOLE; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; VOMITING; WEAKNESS; XEROSTOMIA;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; STOMACH ULCER;

EID: 34247578074     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. European Helicobacter Study group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut. 1997; 41: 8-13.
2. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996; 1: 138-144.
3. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1: 6-19.
4. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, et al. The DU-Mach study, eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole-based triple therapy. Aliment Pharmacol Ther. 1999; 13: 289-295.
5. Saberi-Firoozi M, Massarrat S, Zare S, Fattahi M, Javan A, Etaati H, et al. Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over 1-year follow-up period: a randomized controlled study. Am J Gastroenterol. 1995; 90: 419-423.
6. Kashifard M, Malekzadeh R, Siavoshi F, Mikaeli J, Massarrat S. Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy compromising omeprazole and amoxicillin. Eur J Gastroenterol Hepatol. 1998; 10: 847-850.
7. Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, et al. Various duration of a standard regimen (amoxicillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol. 2001; 13: 915-919.
8. Salman-Roghani H, Massarrat S, Pahlewanzadeh MR, Dashti M. Effect of two doses of metronidazole and tetracycline in bismuth triple therapy on eradication of H.pylori and its resistant strains. Eur J Gastroenterol Hepatol. 1999; 11: 709-712.
9. Pourkhajeh A, Siavoshi F, Malekzadeh R. In vitro sensitivity of H.pylori to antibiotics. Gastroenterology. 1999; 116: A244.
10. Zheng ZT, Wang YB. Treatment of peptic ulcer disease with furazolidonc. J Gastroenterol Hepatol. 1992; 7: 533-537.
11. Segure AM, Gutierres O, Otero W. Furazolidone, amoxicillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1997; 11: 529-532.
12. Liu WZ, Xiao SD, Shi Y, Wu SM, Zhang DZ, Xu WW, et al. Furazolidone-containing short triple therapies are effective in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999; 13: 317-322.
13. van Zwet AA, Thijs JC, van der Wouden EJ, Kooy A. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Aliment Pharmacol Ther. 1997; 11: 533-535.
14. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metrorridazole resistance. Antimicrob Agents Chemother. 2001; 45: 306-308.
15. Howden A, Boswell P, Tovey F. In vitro sensitivity of Campylobacter pyloridis to furazolidone. Lancet. 1986; 2: 1035.
16. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001; 15: 411-416.
17. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004; 19: 89-93.
18. Salman-Roghani H, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2003; 18: 778-782.
19. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion. 2001; 64: 222-225.
20. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, Sotodehmanesh R, Haghpanah B, et al. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit. 2003; 9: 105-109.
21. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter. 2002; 7: 225-231.
22. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther. 2002; 16: 1277-1282.
23. Wong WM, Wong BC, Lu H, Gu Q, Yin Y, Wang WH, et al. One-week omeprazole, furazolidone, and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther. 2002; 16: 793-798.
24. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther. 2000; 14: 299-303.
25. Frota LC, da Cunha Mdo P, Luz CR, de Araujo-Filho AH, Frota LA, Braga LL. Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole-based triple therapy: an open randomized clinical trial. Arq Gastroenterol. 2005; 42: 111-115.
26. Araujo-Castillo R, Pinto-Valdivia JL, Ramirez D, Cok Garcia J, Bussalleu-Rivera A. New ultrashort scheme for Helicobacter pylori infection eradication using tetracyline, furazolidone, and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia. Rev Gastroenterol Peru. 2005; 25: 23-41.
27. Mansour-Ghanaei F, Fallah MS, Shafaghi A. Eradication of Helicobacter pylori in duodenal ulcer disease: tetracycline and furazolidone vs. metronidazole and amoxicillin in omeprazole-based triple therapy. Med Sci Monit. 2002; 8: 27-30.
28. Lu H, Zhang DZ, Hu PJ, Li ZS, Lu XH, Fang XC, et al. One-week regimens containing ranitidine, bismuth citrate, furazolidone, and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicenter, randomized, double-blind study. Aliment Pharmacol Ther. 2001; 15: 1975-1979.
29. Liu WZ, Xiao SD, Hu PJ, Lu H, Cui Y, Tytgat GN. A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin, and famotidine. Aliment Pharmacol Ther. 2000; 14: 1519-1522.
30. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000; 14: 211-215.
31. Xiao SD, Liu WZ, Hu PJ, Xia DH, Tytgat GN. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone, and clarithromycin triple therapy for 1 week. Aliment Pharmacol Ther. 1999; 13: 311-315.
32. Dani R, Queiroz DM, Dias MG, Franco JM, Magalhaes LC, Mendes GS, et al. Omeprazole, clarithromycin, and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther. 1999; 13: 1647-1652.
33. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005; 21: 1419-1424.